Pathology imaging systems market seen reaching $2.29 billion by 2030

The pathology imaging systems market is projected to rise from $1.37 billion in 2025 to $2.29 billion by 2030 as digital pathology, AI tools and cloud platforms expand. North America leads today, while Asia-Pacific is expected to grow fastest as clinical trial activity and remote diagnostics increase.

Why it matters: - Pathology imaging systems support faster and more accurate tissue analysis, which matters for cancer care, chronic disease diagnosis and research. - The market outlook points to rising demand for digital pathology infrastructure as labs, hospitals and trial sponsors move away from manual microscopy. - Growth in this market also signals broader adoption of AI-assisted diagnostics, cloud-based workflows and remote pathology services.

What happened: - The Business Research Company said the pathology imaging systems market is expected to grow from $1.37 billion in 2025 to $1.52 billion in 2026. - The market is projected to reach $2.29 billion by 2030. - The forecast implies a 10.7% CAGR from 2025 to 2026 and a 10.9% CAGR through 2030. - The company published a market update on July 21, 2026, from London. - A free sample report and the full market report are available online.

The details: - Pathology imaging systems are digital platforms and devices that capture, store, analyze and share high-resolution images of tissue samples and laboratory specimens. - The systems are used to improve diagnostic precision and support digital pathology workflows. - AI-driven analysis is becoming a key part of the category. - The report links recent market growth to manual microscopy dependence, slow digital pathology adoption, expensive scanners, a shortage of skilled pathologists and limited data storage. - The report says future growth will be driven by AI-assisted diagnostic tools, cloud-based pathology platforms, precision medicine demand, remote diagnostic services and tighter integration of hospital IT and imaging systems. - The report highlights telepathology and outsourced remote diagnostics as emerging trends. - Standardization of whole slide imaging and interoperability improvements are also expected to advance. - Centralized pathology labs serving multiple hospitals are growing. - Regulators are paying more attention to digital pathology validation. - Laboratory information systems are increasingly being linked with imaging workflows. - In 2025, North America held the largest share of the market. - Asia-Pacific is expected to post the fastest growth during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The forecast reflects a shift from basic image capture toward connected diagnostic ecosystems. - Clinical trials are an important demand driver because they require tissue review, biomarker detection and ongoing monitoring. - Pharmaceutical and biotechnology investment, plus government-backed therapy development, are helping push trial volumes higher. - The Association of the British Pharmaceutical Industry reported that UK clinical trials initiated by pharmaceutical companies rose from 411 in 2022 to 426 in 2023, the second straight annual increase. - That increase suggests more demand for imaging systems in research settings, not just routine diagnostics.

What's next: - Market growth is likely to track continued adoption of AI, cloud tools and telepathology. - Competitive pressure may increase around interoperability, validation and workflow integration. - Regional expansion in Asia-Pacific could narrow the gap with North America if hospital digitization and clinical research activity keep accelerating. - The Business Research Company said its 2026 reports include new market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel forecasting dashboards, hotspot infographics and updated trend analysis.

The bottom line: - Pathology imaging systems are moving from niche digital tools to core diagnostic infrastructure, and the market’s projected climb to $2.29 billion by 2030 shows that shift is accelerating.